IL17A and breast cancer: Research indicates that neutralizing IL‐17 and IFNγ can inhibit the migration of BC cell lines (BCCLs), demonstrating their pathogenic roles [48]; conversely, supplementing IL‐17 enhances BCCL migration, with IFNγ further amplifying this effect.